FDA Approves First Generic Single-Dose Influenza Treatment Ahead of 2026–2027 Flu Season

The U.S. Food and Drug Administration has approved the first generic version of baloxavir marboxil tablets, marking a significant milestone in influenza treatment accessibility. The approval, announced on June 17, 2026, comes ahead of the upcoming flu season and represents the Trump Administration's commitment to expanding access to affordable generic medications. Norwich Pharmaceuticals, Inc. received FDA approval for the generic formulation of Xofluza, the original branded single-dose treatment developed by Genentech, Inc.

Generic baloxavir marboxil is approved for two clinical uses: treatment of acute uncomplicated influenza in patients aged 5 and older who have been symptomatic for no more than 48 hours, and post-exposure prophylaxis following contact with an infected individual. The drug is suitable for patients who are otherwise healthy or at high risk of developing influenza-related complications. According to FDA Director Iilun Murphy, M.D., the approval represents a meaningful advancement in public health, as influenza alone accounts for millions of illnesses annually in the United States.

The availability of a generic alternative is expected to increase competition in the pharmaceutical marketplace, reducing costs and improving patient access to treatment. In the U.S., approximately nine out of ten prescriptions filled are for generic drugs, demonstrating the significant role generics play in healthcare affordability. The most commonly reported side effects include diarrhea, bronchitis, nausea, sinusitis, and headaches. Healthcare providers are advised to review complete prescribing information, as the drug carries warnings regarding increased incidence of treatment-emergent resistance in patients under 5 years of age and is contraindicated in patients with known hypersensitivity to baloxavir marboxil or its ingredients.